原位形成可注射 γ-聚（谷氨酸）/PEG 粘性水凝胶用于控制出血,Biomaterials Science

当前位置： X-MOL 学术 › Biomater. Sci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

原位形成可注射 γ-聚（谷氨酸）/PEG 粘性水凝胶用于控制出血
Biomaterials Science ( IF 5.8 ) Pub Date : 2022-06-24 , DOI: 10.1039/d2bm00525e
Huijun Ye ₁ , Yiwen Xian ₁ , Shurong Li ₁ , Chong Zhang ₁ , Decheng Wu ₁

Affiliation

由于易于给药和微创，快速原位形成的粘性水凝胶是有效止血的有前途的候选者。然而，开发生物相容性和高性能的止血水凝胶而无需任何额外的毒剂仍然是一个挑战。在此，开发了一系列基于N-羟基琥珀酰亚胺 (NHS) 修饰的 γ-聚谷氨酸 (γPGA–NHS) 和四臂聚乙二醇胺 (Tetra-PEG-NH ₂ )的新型可注射粘附水凝胶. 在所有样品中，PGA ₁₀ –PEG ₁₅和 PGA ₁₀ –PEG ₂₀具有较高 PEG 含量的水凝胶表现出快速的凝胶化时间（<20 s）、强的机械强度（压缩模量高达~75 kPa）、良好的粘合性能（~15 kPa）和令人满意的爆破压力（~18-20 kPa）。因此，与纱布和纤维蛋白胶相比，PGA ₁₀ –PEG ₁₅和 PGA ₁₀ –PEG ₂₀水凝胶的止血时间和失血量显着减少。更重要的是，PGA ₁₀ –PEG ₂₀水凝胶还成功用于封闭股动脉外伤。皮下植入实验表明水凝胶在体内具有良好的生物相容性. 所有这些结果有力地支持了所开发的 PGA-PEG 水凝胶可以在紧急情况和临床情况下用作有前途的止血剂。

"点击查看英文标题和摘要"

In situ forming injectable γ-poly(glutamic acid)/PEG adhesive hydrogels for hemorrhage control

Rapidly in situ forming adhesive hydrogels are promising candidates for efficient hemostasis due to their easy administration and minimal invasion. However, development of biocompatible and high-performance hemostatic hydrogels without any additional toxic agents remains a challenge. Herein, a series of novel injectable adhesive hydrogels based on N-hydroxysuccinimide (NHS) modified γ-poly(glutamic acid) (γPGA–NHS) and tetra-armed poly(ethylene glycol) amine (Tetra-PEG-NH₂) were developed. Among all samples, PGA₁₀–PEG₁₅ and PGA₁₀–PEG₂₀ hydrogels with higher PEG contents exhibited rapid gelation time (<20 s), strong mechanical strength (compression modulus up to ∼75 kPa), good adhesive properties (∼15 kPa), and satisfactory burst pressure (∼18–20 kPa). As a result, PGA₁₀–PEG₁₅ and PGA₁₀–PEG₂₀ hydrogels showed a remarkable reduction in hemostasis time and blood loss compared with gauze and fibrin glue. More importantly, the PGA₁₀–PEG₂₀ hydrogel was also successfully used to seal femoral arterial trauma. Subcutaneous implantation experiments indicated a good biocompatibility of the hydrogels in vivo. All these results strongly support that the developed PGA–PEG hydrogels could serve as promising hemostatic agents in emergency and clinical situations.

更新日期：2022-06-24

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南